RxDoctor Payments Data

Jayde Wall, NP

Gerontology · Indianapolis, INNPI 1013566884

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 91.7% of the total across 50 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 9 manufacturers, the largest accounting for just 21.6% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $574 and has fallen 65.5% since, to $198 in 2025.

$2,117in general payments, 2019–2025

Across 50 payments — averaging $42.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$457
  • Eisai Inc.$404
  • Merck$348
  • AstraZeneca$330
  • Immunogen, Inc.$241
  • AbbVie$128
  • plus $210 from 3 others

What the payments were for

  • Food & beverage$1,94292%
  • Education$1758%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
GSK9$457
Eisai Inc.13$404
Merck16$348
AstraZeneca4$330
Immunogen, Inc.2$241
AbbVie2$128
Seagen Inc.1$100
Clovis Oncology, Inc.2$85
Novartis1$25

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,117 in reported general payments places this provider in the 80th percentile of 230 gerontology providers in Indiana.

See all gerontology providers in Indiana

Medicare billing

Part B allowed, 2024
$17,645
Medicare patients
121
Services billed
288

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LynparzaOlaparib18$313,643
EliquisApixaban13$9,010
Megestrol Acetate23$1,277
Lidocaine12$952
Medroxyprogesterone Acetate19$764
Ondansetron Hcl31$657
Potassium Chloride17$574
Dexamethasone Sodium Phosphate14$508
Lidocaine-PrilocaineLidocaine/Prilocaine18$309
Triamcinolone Acetonide12$306
Prednisone16$165
Prochlorperazine Maleate18$161
Gabapentin20$149
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen11$133
Oxycodone Hcl24$94

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaLynparza$330$313,64318 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 230 gerontology providers in Indiana.

Other gerontology in Indianapolis

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →